Non-ATTR Hereditary

Now Enrolling: REFLECTION Natural History Study for Adults with ALECT2 Amyloidosis Alnylam Pharmaceuticals has initiated their natural history study, REFLECTION, which is being conducted to observe and collect information about Leukocyte Chemotactic Factor 2 (ALECT2) Amyloidosis. This study will help researchers learn more about this rare disease, including how it affects the body over time, so that they can potentially develop better ways to diagnose and treat the condition. REFLECTION is enrolling up to 150 people who have been diagnosed with ALECT2 amyloidosis, confirmed by a kidney biopsy. If you haven’t had a kidney biopsy and your doctor thinks your kidney disease may be caused by ALECT2, you may be able to have the biopsy done as part of this study. For more information, and to see if you can be referred to a participating clinical trial site, email clinicaltrials@alnylam.com. More: The REFLECTION natural history study is now being conducted in the United States. This study will help researchers learn more about this rare disease, including how it affects the body over time, so that they can potentially develop better ways to diagnose and treat the condition. All study participants will be asked to allow the study team to review and collect data from their medical records, and to provide blood and urine samples. Study participants who are not on dialysis and have not had a kidney transplant will be asked to complete study visits every 6 months for 4 years. Transportation to and from study visits, or reimbursement for travel-related costs may also be provided to those who qualify. Alnylam Pharmaceutical’s natural history study, REFLECTION, will help researchers learn more about this rare disease, including how it affects the body over time, so that they can potentially develop better ways to diagnose and treat the condition.